{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:30:06Z","timestamp":1787499006172,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,19]]},"DOI":"10.7759\/cureus.99652","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:01:57Z","timestamp":1766181717000},"source":"Crossref","is-referenced-by-count":1,"title":["Massive Submacular Hemorrhage Following Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration"],"prefix":"10.7759","author":[{"given":"Adriana","family":"Kaganovski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nairi","family":"Rostomian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Shrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.04.004","article-title":"Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature","volume":"61","author":"Stanescu-Segall D","year":"2016","unstructured":"Stanescu-Segall D, Balta F, Jackson TL. Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature. Surv Ophthalmol. 2016, 61:18-32. 10.1016\/j.survophthal.2015.04.004","journal-title":"Surv Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.116902","article-title":"Advancements in age-related macular degeneration treatment: from traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnology","volume":"236","author":"Wang Z","year":"2025","unstructured":"Wang Z, Zhang Y, Xu C, Peng A, Qin H, Yao K. Advancements in age-related macular degeneration treatment: from traditional anti-VEGF to emerging therapies in gene, stem cell, and nanotechnology. Biochem Pharmacol. 2025, 236:116902. 10.1016\/j.bcp.2025.116902","journal-title":"Biochem Pharmacol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier JS","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, et al.. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022, 399:729-40. 10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-025-00902-6","article-title":"Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER","volume":"26","author":"Liu C","year":"2025","unstructured":"Liu C, Li S, Wang Z, Li Z, Fang Z, Zhang Y, Gao Y. Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER. BMC Pharmacol Toxicol. 2025, 26:82. 10.1186\/s40360-025-00902-6","journal-title":"BMC Pharmacol Toxicol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2025.2456173","article-title":"A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database","volume":"24","author":"Han F","year":"2025","unstructured":"Han F, Li X, Tao T, Wang J. A pharmacovigilance study on the safety of faricimab in real-world scenario using FDA adverse event reporting system database. Expert Opin Drug Saf. 2025, 24:657-64. 10.1080\/14740338.2025.2456173","journal-title":"Expert Opin Drug Saf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.10.017","article-title":"Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for exudative age-related macular degeneration","volume":"270","author":"Kaufmann GT","year":"2025","unstructured":"Kaufmann GT, Boucher N, Sharma C, Aggarwal N, Starr MR. Submacular hemorrhage rates following anti-vascular endothelial growth factor injections for exudative age-related macular degeneration. Am J Ophthalmol. 2025, 270:172-82. 10.1016\/j.ajo.2024.10.017","journal-title":"Am J Ophthalmol"},{"key":"ref7","article-title":"The mechanism of the bispecific antibody faricimab","volume":"16","author":"Mojumder NI","year":"2019","unstructured":"Mojumder NI, Khanani AM. The mechanism of the bispecific antibody faricimab. Retin Physician. 2019, 16:","journal-title":"Retin Physician"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-022-05885-2","article-title":"Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration","volume":"261","author":"Weber C","year":"2023","unstructured":"Weber C, Bertelsmann M, Kiy Z, Stasik I, Holz FG, Liegl R. Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2023, 261:1413-21. 10.1007\/s00417-022-05885-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-65877-3_2","article-title":"Macular haemorrhages: natural course and risk factors","author":"Feltgen N","year":"2018","unstructured":"Feltgen N. Macular haemorrhages: natural course and risk factors. Management of Macular Hemorrhage. Hattenbach LO (ed): Springer, Cham, Switzerland; 2018. 5-9. 10.1007\/978-3-319-65877-3_2"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.07.028","article-title":"The timing of large submacular hemorrhage secondary to age-related macular degeneration relative to anti-VEGF therapy","volume":"5","author":"Matsunaga DR","year":"2021","unstructured":"Matsunaga DR, Su D, Sioufi K, Obeid A, Wibbelsman T, Ho AC, Regillo CD. The timing of large submacular hemorrhage secondary to age-related macular degeneration relative to anti-VEGF therapy. Ophthalmol Retina. 2021, 5:342-7. 10.1016\/j.oret.2020.07.028","journal-title":"Ophthalmol Retina"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(82)90301-4","article-title":"Experimental subretinal hemorrhage in rabbits","volume":"94","author":"Glatt H","year":"1982","unstructured":"Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982, 94:762-73. 10.1016\/0002-9394(82)90301-4","journal-title":"Am J Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020367","article-title":"Outcomes in the treatment of subretinal macular hemorrhage secondary to age-related macular degeneration: a systematic review","volume":"13","author":"Confalonieri F","year":"2024","unstructured":"Confalonieri F, Ferraro V, Barone G, et al.. Outcomes in the treatment of subretinal macular hemorrhage secondary to age-related macular degeneration: a systematic review. J Clin Med. 2024, 13:367. 10.3390\/jcm13020367","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/444580-massive-submacular-hemorrhage-following-intravitreal-faricimab-injection-for-neovascular-age-related-macular-degeneration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:01:58Z","timestamp":1766181718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/444580-massive-submacular-hemorrhage-following-intravitreal-faricimab-injection-for-neovascular-age-related-macular-degeneration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.99652","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,19]]}}}